Xing Lei, Chang Xin, Shen Lijun, Zhang Chenglu, Fan Yatong, Cho Chongsu, Zhang Zhiqi, Jiang Hulin
State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea.
Asian J Pharm Sci. 2021 Jan;16(1):47-61. doi: 10.1016/j.ajps.2020.06.005. Epub 2020 Jul 17.
Fibrosis is a necessary process in the progression of chronic disease to cirrhosis or even cancer, which is a serious disease threatening human health. Recent studies have shown that the early treatment of fibrosis is turning point and particularly important. Therefore, how to reverse fibrosis has become the focus and research hotspot in recent years. So far, the considerable progress has been made in the development of effective anti-fibrosis drugs and targeted drug delivery. Moreover, the existing research results will lay the foundation for more breakthrough delivery systems to achieve better anti-fibrosis effects. Herein, this review summaries anti-fibrosis delivery systems focused on three major organ fibrotic diseases such as liver, pulmonary, and renal fibrosis accompanied by the elaboration of relevant pathological mechanisms, which will provide inspiration and guidance for the design of fibrosis drugs and therapeutic systems in the future.
纤维化是慢性疾病发展为肝硬化甚至癌症过程中的一个必要过程，这是一种威胁人类健康的严重疾病。最近的研究表明，纤维化的早期治疗是一个转折点，尤为重要。因此，如何逆转纤维化已成为近年来的焦点和研究热点。到目前为止，在开发有效的抗纤维化药物和靶向给药方面已经取得了相当大的进展。此外，现有的研究成果将为实现更好抗纤维化效果的更多突破性给药系统奠定基础。在此，本综述总结了针对肝、肺和肾纤维化等三种主要器官纤维化疾病的抗纤维化给药系统，并阐述了相关病理机制，这将为未来纤维化药物和治疗系统的设计提供启发和指导。
